Norma’s Completion of Quantum AI Algorithm Validation on NVIDIA

Announcement

The norma, a leading quantum computing company, has successfully validated the work of quantum AI algorithms with the help of NVIDIA CUDA-Q. By adopting these algorithms for drug development on CUDA-Q, Norma noticed the computational speed that is 73 times faster in comparison to the standard duration. The company has also protected use cases for quantum AI in its plans and drug development to extend its validation work into several fields.

Norma’s Efforts

Norma currently tests and evaluates the performance of its very own quantum AI algorithms on the NVIDIA CUDA-Q platform. The CUDA-Q eases the integration of QPUs and GPUs and contributes to quantum-classical hybrid operations, involving delivering as a significant technology to leverage the development and implementation of quantum algorithms. Norma is solo playing around in developing the quantum AI algorithms suitable throughout areas like defense, finance, and biotechnology. The company is busy working on projects to reinforce these algorithms in the CUDA-Q line and evaluate their performance.

The project was brought into the limelight, associated with the joint research with Kyung Hee University Hospital at Gangdong, focused on exploring novel drug candidates. Because of the broadness of the chemical search area, the traditional AI approaches have addressed computational limitations in drug discovery. To win over these limitations, the norma’s quantum AI team is working towards developing algorithms like QGAN, QCBM, and QLSTM. These algorithms are brilliantly trained and validated with the help of numerous quantum simulators.

The latest test shows that the NVIDIA CUDA-Q has a significantly higher level of computational performance in comparison to other simulators. Norma has used CUDA-Q space with the help of NVIDIA GH200 and NVIDIA H200 GPUs to test its quantum AI algorithms for drug development. The result of this test highlighted that the NVIDIA CUDA-Q prominently beat the traditional CPU-based methods.

By serving realistic and fast verification of algorithms before the deployment on real quantum hardware, the project has diminished development time and cost while improving optimization potential. The validation of the test is effective as it specifically elaborates on the practical applicability of quantum AI technology in drug discovery, also enabling informative data to shape the future of quantum hardware throughout diverse fields.

Views and Statements from the Company Leaders

CEO of Norma, Hyunchul Jung, said, “The project is the best example of the partnership between the international and domestic quantum technology companies and hospitals, highlighting the practical capability of quantum technologies.”